Posted by Michael Wonder on 09 Jun 2022
AlgoTx’s ATX01 granted fast track designation by FDA for chemotherapy-induced neuropathic pain
9 June 2022 - AlgoTx announced today that it has received fast track designation from the U.S. FDA for the development of ATX01 in chemotherapy-induced neuropathic pain.
ATX01 recently obtained an IND for its Phase 2 trial in CIPN due to start in late 2022, and an orphan drug designation for development in erythromelalgia.
